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Summary 
Objective: To describe the impact of a collaborative Italian diagnostic pathway offering ambulatory blood pressure (BP) monitoring 
(ABPM) in High Risk Antenatal Clinic (HRAC) pregnant women. The study included 395 pregnant women evaluated at HRAC between 
2012 and 2016, while analyzing demographic, clinical characteristics, and prescription of ABPM. Pregnant women were firstly seen when 
gestational age was 19.6 ± 9.6 weeks. In at least one-third of cases, ABPM was followed by medical intervention aiming to modify 
the pre-existing therapeutic treatment. Hypertension and overweight were the main reasons for performing ABPM. WCH: white-coat 
hypertension.
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lence (NICE) guidelines, pregnant women should undergo 
more frequent BP measurements in the presence of the fol- 
lowing risk factors: age 40 years or older, nulliparity, preg- 
nancy interval of more than ten years, family history or 
previous history of PE, body mass index 30 kg/m2 or above, 
pre-existing vascular disease such as hypertension, pre-ex- 
isting renal disease, and multiple pregnancy [2]. For man- 
agement of hypertension, ambulatory BP monitoring 
(ABPM) appears to be better than clinic BP, since around- 
the-clock BP values are strongly related to target organ 
damage, vascular risk, and long-term patient prognosis [5]. 
The aim of this study was to review the impact of a col- 
laborative diagnostic pathway between the High Risk An- 
tenatal Clinic (HRAC), Obstetrics and Gynaecology Unit, 
and the Hypertension Center, Clinica Medica Unit, at the 
General Hospital of Ferrara, Region Emilia-Romagna of 
Italy, offering ABPM in selected cases of pregnant women. 
Materials and Methods 
This retrospective study, conducted in agreement with the Dec- 
laration of Helsinki of 1975, revised in 2013, included all pregnant 
women evaluated at the local HRAC between January 1, 2012, 
and December 31, 2016, recorded in the database of the HRAC, 
and maintained by midwives. All subjects gave informed written 
Introduction 
Hypertensive disorders in pregnancy are a leading cause 
of maternal morbidity and mortality worldwide. On one 
hand, a condition of hypertension developed during preg- 
nancy impacts development of high blood pressure (BP) 
values increasing cardiovascular risk of women [1]. On the 
other, diagnosis and acute management of severe hyper- 
tension is crucial in order to reduce maternal mortality and 
screen for pre-eclampsia (PE) [2]. 
Data from the United States report that PE affects about 
3% of pregnancies, and all other hypertensive disorders 
complicate approximately 5-10% of pregnant women.[3] 
PE represents common and dangerous complication of 
pregnancy, and causes maternal and perinatal illness. More- 
over, it is responsible for a high proportion of maternal and 
infant deaths. Common findings during PE are increased 
BP and proteinuria, and generalized dysfunction of the ma- 
ternal endothelium, secondary to exaggerated systemic in- 
flammatory response mediated by cytokines [4]. 
Hypertension during pregnancy has been classified into 
four categories: 1) preeclampsia-eclampsia, 2) chronic hy- 
pertension (of any cause), 3) chronic hypertension with su- 
perimposed PE, and 4) gestational hypertension [1]. 
According to National Institute for Health and Care Excel- 
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Table 1. — Reasons for referral of pregnant women to high
risk antenatal clinic. 
Fetal growth restriction 27 (6.8%) 
Diabetes mellitus 134 (33.9%) 
Type I diabetes mellitus 24 (17.9% of 
diabetic women) 
Type II diabetes mellitus 4 (3% of 
diabetic women) 
Gestational diabetes 106 (79% of 
diabetic women) 
Pre-eclampsia during a previous pregnancy 14 (3.5%) 
Hypertension 77 (19.4%) 
Overweight 97 (24.5%) 
Excessive weight gain 11 (2.8%) 
Rheumatological diseases 61 (15.4%) 
Heart diseases 19 (4.8%) 
Kidney diseases 14 (3.5%) 
consent for data recording and analysis. 
The present HRAC functions as a referral center for a catch- 
ment area in North Eastern Italy. Pregnant women, who have risk 
factors according to a regional protocol, are referred from the local 
antenatal clinics. A senior Obstetrician would see each patient, 
perform ultrasound and Doppler studies, establishing the man- 
agement. 
The following parameters were recorded in the database: age, 
history of diabetes mellitus, hypertension, rheumatological dis- 
eases, heart diseases, kidney diseases, overweight that could be 
developed before or during pregnancy, PE, week of pregnancy at 
the time of every evaluation, presence of fetal complications such 
as fetal growth restriction, type of delivery, miscarriage or abor- 
tion, [6] gestational age and weight of the baby at the time of de- 
livery (according to Italian birthweight charts), and week of 
pregnancy at the time of ABPM changes in anti-hypertensive 
treatment. Type of treatment was not analyzed, since only treat- 
ment variation happening after ABPM was taken into considera- 
tion. In agreement with national dispositions by law in terms of 
privacy, all potential identifiers from the database provided for 
this study have been removed. Every record corresponded to a 
single patient identified by a progressive number. Since HRAC is 
a hub center, some women had their deliver elsewhere, therefore 
data about the final weeks of their pregnancy could not be col- 
lected. Thus, these cases were excluded from the present analysis. 
The University and General Hospital of Ferrara is provided with 
a Hypertension Center, an ambulatory setting being part of the 
Clinica Medica Unit, a 24-bed complex unit of internal medicine. 
This Center serves as the hub third-level facility for both the town 
of Ferrara and provincial area (around 350,000 inhabitants) and 
neighbouring areas, with a consolidated yearly activity of ap- 
proximately 1,900 ABPM procedures and 1,500 visits. 
ABPM was performed during 24 hours using a validated 
device validated for pregnancy by the British Hypertension Soci- 
ety [https://bihsoc.org/bp-monitors/for-specialist-use/]. BP was 
measured every 15 minutes or at intervals of not more than 30 
minutes during daytime (06:00 - 23:00) and every 30 minutes or 
at intervals of no more than 60 minutes during night-time (23:00 
– 06:00).
Data are expressed as absolute numbers, means, and percent- 
ages. Furthermore, the authors drew a decision tree analyzing con- 
ditions associated with prescription of ABPM. Statistical analysis 
was performed using SPSS 13.0, 2004, for statistical analysis of 
the demographic data. 
Figure 1. — Decision tree analysis evaluating patients who un- 
derwent ambulatory blood pressure monitoring (ABPM). Hyper- 
tension and overweight are the main reasons for performing 
ABPM. 
Results 
The study included 395 pregnant women (87 in 2012, 
101 in 2013, 64 in 2014, 67 in 2015, and 76 in 2016), con- 
sidered at high risk. Their mean age was 33.9 ± 5.6 years, 
and they were mainly of Mediterranean origin (91%). They 
were firstly seen when gestational age was 19.6 ± 9.6 
weeks. 
Reasons for referral to HRAC were rheumatological dis- 
eases in 61 (15.4%) cases, heart diseases in 19 (4.8%), and 
kidney diseases in 14 (3.5%). Detailed information are re- 
ported in Table 1. 
Fetal growth restriction was diagnosed in 27 (6.8%) pa- 
tients. Diabetic pregnant women were 134 (33.9%) of 
whom 24 (17.9%) that had type I diabetes mellitus, four 
type II (3%), and 106 (79%) gestational diabetes. Pre- 
eclampsia during a previous pregnancy was reported in 14 
(3.5%) cases, and hypertension was diagnosed in 77 
(19.4%) cases. Overweight was present in 97 (24.5%) preg- 
nant women, and excessive weight gain during pregnancy 
was observed in 11 (2.8%) cases. 
A strong collaboration between HRAC and Hypertension 
Center is active for many years. Hypertension, but also 
overweight, represent the main causes for ABPM request 
and referral to Hypertension Center. The decisional tree 
analysis is shown in Figure 1. In the sample population ob- 
ject of the present study, ABPM was carried out at the fol- 
lowing gestational age: 19 ± 8, 22 ± 8, 26 ± 8 weeks and 
beyond. A single ABPM procedure was performed in 87 
(22%) cases, and multiple ABPM measures were necessary 
in 100 (25%) cases. In at least one-third of cases of single 
measurement, ABPM was followed by medical interven- 
tion aimed to modify the pre-existing therapeutic treatment. 
In details, range of variation to antihypertensive treatment 
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Table 2. — Number of ABPM procedures and variation to antihypertensive treatment (AHT). 
was 33% to 91% (Table 2). 
Three hundred and thirty-three (87.7%) women had suc- 
cessful delivery, and 41 (6.3%) women were lost during 
follow-up (delivery in other hospitals or other provinces). 
In details, among women with successful delivery, sponta- 
neous delivery occurred in 186 (49%) cases and caesarean 
section in 147 (38.7%) cases. Mean birth weight of new- 
borns was 3,225 ± 652 grams, and 14 newborns were con- 
sidered underweight (4.7%) (less than the 10th centile). 
Miscarriages were 18 (4.7%), and abortions were 3 (0.7%). 
Discussion 
In this study, hypertension and overweight were the main 
factors determining prescription of ABPM in HRAC. The 
population of this study was characterized by a high risk 
for PE/eclampsia, and the result of careful management of 
high risk patients was that 87.7% of women had a baby, a 
percentage that could theoretically increase up to 94% if 
we remember that 6.3% of pregnant women were lost dur- 
ing follow-up. These findings are not so different from data 
shown by NICE guidelines, where perinatal mortality of in- 
fants without congenital abnormality in women with pre- 
eclampsia was 5% [7]. 
Evaluation of the role of ABPM in pregnancy associated 
hypertension has begun since the late nineties. In a study 
using ABPM on a limited sample of patients, accounting 
73 controls, 48 patients with pregnancy-induced hyperten- 
sion, 38 with PE, and 53 with mild to moderate chronic hy- 
pertension, Benedetto et al. concluded that ABPM during 
pregnancy enabled quantitative and qualitative evaluations 
of the hypertensive status [8]. Higgins et al. [9] evaluated 
ABPM in 1048 women at 18 to 24 weeks of gestation; of 
these 2.2% developed PE and 6.1% developed gestational 
hypertension. Values recorded during ABPM were higher in 
both the pre-eclamptic and gestational hypertensive group 
compared with the normotensive group, with no differences 
between the pre-eclamptic and the gestational hypertensive 
group for any of the BP parameters analyzed [9]. Bellomo 
et al. [10] assessed the prognostic value of white-coat hy- 
pertension (WCH) during pregnancy in a prospective co- 
hort study. Duration of pregnancy was shorter in the 
hypertensive patients, but similar in the normotensive and 
WCH pregnant women. Incidence of PE was higher in hy- 
pertensive women, but similar in the normotensive and 
WCH groups. Frequency of cesarean delivery was lower in 
the normotensive than in the WCH and true hypertensive 
groups. Neonatal weight was lower in the hypertensive 
pregnant women than in the normotensive and WCH 
groups. The authors concluded that in women with elevated 
BP during their third trimester of pregnancy, ABPM was 
superior to office BP, for prediction of the outcome of preg- 
nancy. Outcomes in the normotensive and WCH group 
were comparable, but the increased incidence of cesarean 
delivery in the WCH group could reflect physicians’ deci- 
sion-making processes derived from office BP [10]. Waugh 
et al. [11] examined the relationship between ABPM dur- 
ing pregnancy and birth weight in a population of 237 
women considered to have hypertension according to of- 
fice BP. After adjustment for potential confounders, e.g., 
maternal age, maternal weight, smoking status, ethnicity, 
and gestational age at delivery, authors found a significant 
inverse association between daytime ambulatory diastolic 
BP measurement and birth weight. An increase of 5 mm Hg 
in daytime mean diastolic BP was associated with a fall in 
birth weight of 68.5 grams [11]. Brown et al. [12] found 
that night-time hypertension was detected in 59% of cases 
with PE and gestational hypertension, and night-time hy- 
pertensives also had higher routine sphygmomanometer 
BPs than women with normal sleep BP, and higher awake 
ABPM. However, the role of ABPM during pregnancy is 
still a matter of debate. The Society of Obstetric Medicine 
Australia and New Zealand (SOMANZ) guidelines for 
management of hypertensive disorders of pregnancy en- 
dorsed ABPM with the major role in identifying women 
with WCH, in order to avoid inappropriate treatment [13]. 
ABPM may be particularly useful in women before 20 
weeks of gestation, since approximately one-third of preg- 
nant women could show WCH or ‘office’ hypertension just 
in this period [13]. In fact, about fifty percent of pregnant 
women with WCH would not be treated with antihyper- 
tensive therapy, while the other fifty percent would become 
hypertensive, with ABPM confirmation. On the contrary, 
ABPM could be less useful in screening for WCH in the 
second half of pregnancy due to its poor sensitivity and 
specificity [13]. On one hand, Magee et al. [14] in their re- 
cent revision on diagnosis, evaluation, and management of 
hypertensive disorders in pregnancy, classified the relevant 
existing evidence related to the use of ABPM as of very 
low/weak quality. On the other, according to the 2013 rec- 
ommendations for the diagnosis of adult hypertension, 
ABPM should be considered the gold standard for diagno- 
sis of hypertension in pregnancy and the screening of preg- 
nant women at high risk for other complications during 
ABPM Women (n) Women (%) Variation to AHT (n) Variation to AHT (%) 
1 87 22 29 33.3 
2 55 13.9 29 34.5 
3 34 8.6 13 38.2 
>3 11 2.8 10 90.9 
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gestation [15]. 
Evidence-based data able to support recommendations 
about diagnosis and management of hypertension during 
pregnancy is limited by ethical and practical issues, in fact 
there are not homogenous and worldwide accepted cut-off 
thresholds for diagnosing and treating hypertension in preg- 
nancy [7, 16]. In the present study, ABPM could be con- 
sidered a helpful method able to help obstetricians not only 
in anti-hypertensive prescription, but also in establishing 
BP values in obese pregnant women. Obese women have 
been reported to have a significant increased risk of preg- 
nancy induced hypertension [17]. 
Conclusions 
Diagnosis and management of hypertension during preg- 
nancy could sometimes be difficult, but evaluation of out- 
of-office BP by ABPM might help obstetricians in classify- 
ing hypertension during pregnancy. ABPM, in fact, is use- 
ful for diagnosis of WCH and masked hypertension, and 
for evaluation of night-time BP, the latter having an early 
prognostic value [18]. Precise definition of all aspects of 
hypertension could help investigation of novel prognostic 
factors, improve treatment, and have positive impact on 
both mother’s and newborn’s outcomes. Moreover, it has 
to be stressed that surveillance against hypertension and 
metabolic disorders begins, and does not cease, with deliv- 
ery. A close interdisciplinary collaboration between obste- 
tricians, midwifes, pediatricians, and hypertension 
specialists may represent first crucial point for prevention 
of metabolic syndrome at a later age. In this view, ABPM 
data analysis could favor tailored personalized therapeutic 
approach, suggesting the right time for hypertension treat- 
ment [19], to achieve better prognostic outcomes. 
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